GlassScriptPhysician profile
Jadranka Popovic
NPI 1538100193
$186,686.72
in general payments reported to CMS, 2019-2025
20 companies · $39K in 2025
The $39K reported for 2025 was more than what 96% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,126 · 2020: $91.13 · 2021: $14K · 2022: $34K · 2023: $40K · 2024: $58K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $128K · Honoraria: $6,245 · Food and Beverage: $2,297 · Travel and Lodging: $297 · Education: $31.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $127,795.89 |
| Honoraria | $6,245.00 |
| Food and Beverage | $2,297.21 |
| Travel and Lodging | $296.52 |
| Education | $31.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $150,354.70 | 2021-2025 | |
| Tolmar Pharmaceuticals, INC. | $11,067.96 | 2019-2022 | |
| Eton Pharmaceuticals, INC. | $8,220.61 | 2022-2025 | Alkindi, Khindivi, Increlex |
| Abbvie INC. | $6,849.98 | 2019-2025 | |
| Tolmar, INC. | $6,785.14 | 2023-2025 | Fensolvi |
| Novo Nordisk INC | $1,043.92 | 2019-2025 | Sogroya, Norditropin |
| Vertex Pharmaceuticals Incorporated | $650.00 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $487.25 | 2022-2025 | Skytrofa |
| Ultragenyx Pharmaceutical INC. | $327.76 | 2022-2023 | Crysvita |
| Saol Therapeutics INC. | $258.33 | 2019 | |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $111.49 | 2025 | |
| Tandem Diabetes Care, INC. | $102.53 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Biomarin Pharmaceutical INC. | $94.44 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $60.56 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $49.04 | 2019-2020 | |
| Rhythm Pharmaceuticals, INC. | $31.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $28.17 | 2019 | |
| Endo Pharmaceuticals INC. | $20.10 | 2022 | |
| Pfizer INC. | $18.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jadranka Popovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.